SCHEMBL5035163

SCHEMBL5035163

O=C(c1ncccc1O)N1CCC2(CCNCC2)CC1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SPR P35270 1/20 0.66
GABRD O14764 2/20 0.52
GABRA1 P14867 2/20 0.52
GABRB1 P18505 2/20 0.52
GABRA5 P31644 2/20 0.52
GABRA3 P34903 2/20 0.52
GABRA2 P47869 2/20 0.52
GABRB2 P47870 2/20 0.52
GABRA4 P48169 2/20 0.52
CYP2D6 P10635 4/20 0.49
CYP3A4 P08684 2/20 0.49
TSHR P16473 2/20 0.49
CYP1A2 P05177 2/20 0.48
CYP2C9 P11712 2/20 0.48
CYP2C19 P33261 2/20 0.48
MEN1 O00255 1/20 0.48
USP2 O75604 1/20 0.48
ALDH1A1 P00352 1/20 0.48
HPGD P15428 1/20 0.48
MAPK1 P28482 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9193063 0.79 SPR (0.67) SPRTSHRCYP2C19MEN1ALDH1A1
SCHEMBL4239995 0.79 GABRD (0.50) GABRDGABRA1GABRB1GABRA5GABRA3
SCHEMBL2140056 0.78 SPR (0.65) SPRTSHRCYP2C19ALDH1A1HPGD
SCHEMBL2842730 0.76 SPR (0.56) SPRCYP2D6CYP3A4TSHRCYP1A2
SCHEMBL5446400 0.76 CHRM2 (0.65) GABRDGABRA1GABRB1GABRA5GABRA3
SCHEMBL4229238 0.76 GABRD (0.71) GABRDGABRA1GABRB1GABRA5GABRA3
SCHEMBL5436686 0.74 GABRD (0.73) GABRDGABRA1GABRB1GABRA5GABRA3
SCHEMBL13805591 0.72 GABRD (0.60) GABRDGABRA1GABRB1GABRA5GABRA3
SCHEMBL31533253 0.72 CYP3A4 (0.49) GABRDGABRA1GABRB1GABRA5GABRA3
SCHEMBL4661842 0.71 PDE10A (0.49)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1926730-A1 NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES AstraZeneca AB (SE) 2008-06-04 EP disclosed
WO-2007030061-A1 NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES ASTRAZENECA AB (SE) 2007-03-15 WO disclosed